Marksans Pharma has announced its Q3 results, with the Board of Directors approving the unaudited financial results for the quarter and nine months ended December 31, 2025. The company’s statutory auditors, M S K A & Associates LLP, have submitted a Limited Review Report with an unmodified opinion. Additionally, M S K A & Associates converted from a partnership to an LLP effective January 12, 2026.
Financial Performance
Marksans Pharma reported its unaudited standalone financial results for the quarter and nine months ended December 31, 2025. The Board of Directors approved these results on February 5, 2026. The Limited Review Reports submitted by the Statutory Auditors indicated an unmodified opinion.
Key Financial Figures (Standalone)
- Revenue from operations: ₹3,397.29 million for Q3, ₹9,799.04 million for nine months.
- Profit After Tax (PAT): ₹609.12 million for Q3, ₹2,087.75 million for nine months.
Key Financial Figures (Consolidated)
- Revenue from operations: ₹7,544.27 million for Q3, ₹20,948.24 million for nine months.
- Profit After Tax (PAT): ₹1,136.90 million for Q3, ₹2,710.32 million for nine months.
Auditor Update
The Company’s statutory auditors, M SK A & Associates, have converted from a partnership firm into a limited liability partnership (LLP), effective January 12, 2026. The firm will now operate as MSKA & Associates LLP.
New Subsidiaries
Marksans Pharma formed two new wholly-owned subsidiaries post-quarter: Marksans Pharma (Europe) Limited in Ireland (incorporated January 16, 2026) and Marksans (Canada) Inc. in Canada (incorporated January 22, 2026).
Employee Stock Option Scheme
Marksans Employee Stock Option Scheme 2024 was approved and on September 24, 2025, the Company granted 400,000 equity stock options to employees.
New Labour Codes Impact
Adoption of the New Labour Codes resulted in an incremental impact of ₹28.10 million recognized as Employee Benefits Expense.
Source: BSE
